Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program

0
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Accleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-3 diagnostic test in order to help address the testing shortages across the U.S. Mammoth’s CRISPR-based approach could potentially offer a significant solution to…
« Previous post: | Next post: »